Integrated filing-pdf
BANKA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Banka BioLoo Limited reported a strong turnaround in FY2026 with standalone PAT of Rs. 38.21 lakhs versus a loss of Rs. 929.64 lakhs in FY2025. Standalone revenue grew 8.65% to Rs. 5,975.76 lakhs. The auditors issued an unmodified (unqualified) opinion on both standalone and consolidated results. However, the auditors flagged a material uncertainty regarding Enzotech Solutions Pvt Ltd (wholly-owned subsidiary), which has filed for Corporate Insolvency Resolution Process (CIRP) under IBC. An emphasis of matter was raised on Rs. 687.44 lakhs (25% of trade receivables) receivable from government bodies, including Rs. 125.26 lakhs outstanding for over 2 years with no provision made. The company also reported an exceptional item of Rs. 29.52 lakhs due to new labour code implementation. Other key appointments include Ms. Srilakshmi Manjula Chaitanya Chunduru as Company Secretary and SMAB & Associates as Internal Auditors.
While the company returned to profitability with positive operating cash flows of Rs. 254.49 lakhs (standalone), investors should note the going concern risk flagged for the Enzotech subsidiary and the large outstanding government receivables with no provisions. The EBITDA margin expanded from 4.18% to 7.17% indicating improved operational efficiency.